BCTX
BriaCell Therapeutics Corp. [BCTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BCTX Stock Summary
Top 10 Correlated Stocks
BCTX
In the News
BCTX Financial details
Company Rating
-
Market Cap
39.79M
Income
-12.14M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
10 Jun 2024
P/E
-6.11
Forward P/E
-
PEG
-22.91
P/S
-
P/B
28.42
P/C
-
P/FCF
-2.78
Quick Ratio
13.06
Current Ratio
17.59
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
73.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-291.89%
-
-
-
-
SMA20
8.63%
SMA50
-12.14%
SMA100
-43.14%
Inst Own
-
Inst Trans
-
ROA
-68%
ROE
616%
ROC
-1.07%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.19-7.67
52W High
-55.43%
52W Low
+56%
RSI
40.37
Rel Volume
1.34
Avg Volume
90.41K
Volume
121.31K
Perf Week
-5.17%
Perf Month
-23.9%
Perf Quarter
-66.23%
Perf Half Y
-81.09%
-
-
-
-
Beta
1.754
-
-
Volatility
0.13%, 0.24%
Prev Close
-11.61%
Price
3.12
Change
-11.86%
Company Profile
- Volume Average 90.41K
- Market Capitalization 39.79M
- Employee 16
- CEO Dr. William V. Williams M.D.
- Headquarters West Vancouver,BC,CA
- IPO Date 2012-03-14
-
Website
https://www.briacell.com 
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
